Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep:107:80-82.
doi: 10.1016/j.clinbiochem.2022.06.004. Epub 2022 Jun 15.

Antibody response to SARS-CoV-2 booster vaccines

Hanna S Loving  1 , David B Sacks  1 , Roa Harb  2
Affiliations

Antibody response to SARS-CoV-2 booster vaccines

Hanna S Loving et al. Clin Biochem. 2022 Sep.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels following booster shots with Moderna or Pfizer vaccines. A, Anti-spike protein (anti-S) levels increased significantly post-booster (Wilcoxon test; N = 91, median difference = 22804 U/mL, 95% CI = 17305 – 20,516 U/mL, P <.0001). B, Pre-booster anti-S levels did not differ by months since vaccine second shot (0.38% increase [95% CI: –0.63 – 1.39%] per day, P =.50). Solid circles represent individual anti-S levels; shaded area represents linear regression with 95% confidence interval. C, Pre-booster anti-S levels by vaccine type (Moderna: N = 65, median = 1223 U/mL, 95% CI = 873 – 1365 U/mL; Pfizer: N = 26, median = 796 U/mL, 95% CI = 512 – 1399 U/mL). D, Pre-booster anti-S levels by gender (women: N = 49, median = 1056 U/mL, 95% CI = 782 – 1379 U/mL; men: N = 42, median = 1014 U/mL, 95% CI = 749 – 1353 U/mL). E, Pre-booster anti-S levels by age group (18–29 yr: N = 12, median = 930 U/mL, 95% CI = 630 – 1365 U/mL; 30–39 yr: N = 20, median = 1261 U/mL, 95% CI = 782 – 2215 U/mL; 40–49 yr: N = 21, median = 1280 U/mL, 95% CI = 654 – 1678 U/mL; 50–64 yr: N = 30, median = 1081 U/mL, 95% CI = 725 – 1399 U/mL; 65–74 yr: N = 6, median = 564 U/mL, 95% CI = 0.4 – 1353 U/mL; 75–84 yr: N = 2, median = 925 U/mL, 95% CI = 869 – 981 U/mL). C-E, Median post-booster levels for all datasets (vaccine type, gender, age group) except age groups 65–74 yr (N = 6, median = 21487 U/mL) and 75–84 yr (N = 2, median = 15813 U/mL) were > 25000 U/mL. F, Anti-S levels were negative (P1) or low (P2) in two participants who reported chemotherapeutic and disease modifying drugs, respectively. Data were plotted on linear (A, C, D, E) and logarithmic (B, F) scales. Asterisk denotes statistical significance. Dashed lines represent cutoff threshold at 0.8 U/mL. CI: confidence interval; P: participant; yr: Year.
See this image and copyright information in PMC

References

    1. Lustig Y., Sapir E., Regev-Yochay G., Cohen C., Fluss R., Olmer L., Indenbaum V., Mandelboim M., Doolman R., Amit S., Mendelson E., Ziv A., Huppert A., Rubin C., Freedman L., Kreiss Y. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. LancetRespir Med. 2021;9(9):999–1009. - PMC - PubMed
    1. Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., Castellino F., Flach B., Lin B.C., O’Connell S., McDanal C., Eaton A., Sarzotti-Kelsoe M., Lu Y., Yu C., Borate B., van der Laan L.W.P., Hejazi N.S., Huynh C., Miller J., El Sahly H.M., Baden L.R., Baron M., De La Cruz L., Gay C., Kalams S., Kelley C.F., Andrasik M.P., Kublin J.G., Corey L., Neuzil K.M., Carpp L.N., Pajon R., Follmann D., Donis R.O., Koup R.A. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50. - PMC - PubMed
    1. Loving H.S., Stallcup P., Burbelo P., Cohen J., Remaley A., Sacks D.B., et al. Early Antibody Temporal Responses to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Vaccinated Subjects Determined by the cobas 6000 Spike Assay. Arch. Pathol. Lab. Med. 2022 Jan;146(1):9–10. - PMC - PubMed
    1. Barda N., Dagan N., Cohen C., Hernán M.A., Lipsitch M., Kohane I.S., Reis B.Y., Balicer R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100. - PMC - PubMed
    1. Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50. Available from: https://www.science.org/doi/10.1126/science.abm3425. - PMC - PubMed